The IJTLD is the reference for clinical research and epidemiological studies on lung health worldwide, including articles on TB, TB-HIV and respiratory diseases such as COVID-19, asthma, COPD, child lung health and the hazards of tobacco and air pollution.
The IJTLD is evolving. Our content including Editorials, Original Articles and Correspondence, alongside new article formats for Minireviews, Clinical Standards, Letters and Literature Highlights. The Journal is also growing in impact – the 2022 Impact Factor is 4.0 – and we are focused on improving the breadth and impact of our articles.
We use single-anonymous peer review (i.e., the reviewers know the identify of the authors of an article, but the authors do not know the identity of the reviewers). This allows reviewers to give feedback without fear of any repercussions.
Our Editor-in-Chief works alongside an active Editorial Board to minimise the time taken for key peer review stages so the process is as quick as possible. Data for 2023 is:
8 Days
First Decision
3 Days
Immediate Reject
27 Days
Peer review
Before submission, authors should download the following forms to check that they have complied with requirements
- Instructions for Authors (PDF)
- House Style Guide
- Author Checklist (PDF)
- Online Submission Instructions (PDF)
If you exceed our recommended article lengths additional fees may apply – see Journal Publication Charges
If you experience difficulties of any kind, please do not hesitate to e-mail the Editorial Office.
Please note that the copyright form (the e-form) must be submitted by the corresponding author online, after article submission. In the event of acceptance all authors will be requested to log on to complete the form online.
The IJTLD can be viewed online here.